The latest report by IMARC Group, titled “Targeted DNA/RNA Sequencing Market Report by Technology (NSG, and Others), Workflow (Presequencing, Sequencing, Data Analysis), Application (Human Biomedical Research, Plant and Animal Sciences, Drug Discovery, and Others), Type (DNA-Based Targeted Sequencing, RNA-Based Targeted Sequencing), End User (Hospitals & Clinics, Academic & Research Institutes, Pharma & Biotech Companies), and Region 2025-2033,” offers a comprehensive analysis of the targeted DNA/RNA sequencing market. The report also includes competitor and regional analysis, along with a breakdown of segments within the industry.
The global targeted DNA/RNA sequencing market size reached USD 13.9 Billion in 2024. Looking forward, IMARC Group expects the market to reach USD 48.1 Billion by 2033, exhibiting a growth rate (CAGR) of 14.77% during 2025-2033.
Request Free Sample Report: https://www.imarcgroup.com/targeted-dna-rna-sequencing-market/requestsample
Targeted DNA/RNA Sequencing Market Dynamics:
- Advancements in Sequencing Technologies and Accuracy
Recent advancements in sequencing technologies, particularly Next Generation Sequencing, have impacted Targeted DNA/RNA Sequencing Market. Innovations like CRISPR, long read sequencing, and better bioinformatics are improving the economics, accuracy and throughput of targeted sequencing. For these reasons, researchers and clinicians can study genetic variations, mutations, and expression profiles in a resolved manner that has never been experienced before. Emerging are technologies that provide more value in understanding cancer, cardiovascular diseases and other rare genetic disorders.
The increasing precision with respect to specific genes, mutations and variants provides even more value to diagnostic and therapeutic uses of DNA and RNA sequencing. The international efforts to precisely target the mutations associated to specific cancers through precision medicine of different strokes and chemotherapies will expand tour horizons. Health care, agriculture, and biotechnologies all can expect to see sharper mutation-focused therapies that will have a profound and rapid impact on the field. In addition, improving targeted sequencing techniques can connect with more industries and businesses. Thus, the potential of targeted sequencing is limitless.
- Increase in Personalized Medicine and Companion Diagnostics
The increase in prevalence of patient population has also led to an increased requirement for personalized treatment which is believed to be the key reason for the growth of the Targeted DNA/RNA Sequencing market. With the increasing understanding of the fact that there has to be a structural genomic difference for a treatment to work necessitated the inclusion of targeted sequencing into precision medicine. Sequencing allow for the understanding of the genetic variation that could affect the effectiveness of a treatment thereby fostering the creation of more targeted therapeutic options.
In addition, with the genetic tests which are conducted with certain medications to understand how patients would respond to them, companion diagnostics are becoming more important especially in the field of oncology. Therefore, the Use of targeted sequencing is growing in clinical applications where it supports decision making on treatment plans, evaluation of the effectiveness of the drug and projections of outcomes for patients. There are pharmaceutical companies who are also employing sequencing technologies in their search for new drugs giving rise to a good business opportunity. As such since personalized medicines is expected to progress, the inclusion of high fixation targeted sequencing techniques is also likely to multiply making the market growth even promising.
- Increased Focus on Biomarker Discovery and Drug Development
Biomarker discovery for diagnosing, predicting and prognosing diseases and predicting response to therapy is one of the factors that augments the growth of the Targeted DNA/RNA Sequencing Market. The capability to detect and verify novel biomarkers through high throughput sequencing technologies supports early diagnosis of the disease as well as tracking of the disease progress. The increasing occurrence of chronic conditions such as cancer, diabetes, and some neurological disorders raises the demand for accurate, noninvasive markers to detect and track diseases earlier and easier.
Targeted DNA/RNA Sequencing is becoming more common in drug trials and the development of new drugs for the reasons of finding new targets and tailoring therapy. It can also allow drug makers to lower the risk of side effects by pinpointing specific genetic markers that are relevant to the condition being treated. In addition, targeting promising biomarkers will unquestionably accelerate drug development aided by artificial intelligence and machine learning with sequencing technologies. The biomarker discovery and development market is growing and therefore is the targeted sequencing which is important for both precision medicine and drug development and the industry as a whole.
Targeted DNA/RNA Sequencing Market Trends
The Targeted DNA/RNA Sequencing market is experiencing several fundamental transformations which will define the era of genomics and healthcare. So, the growing incorporation of sequencing techniques with artificial intelligence (AI) and machine learning (ML) has been one of the notable trends. These advanced computational methods are considerably improving the power and precision of data analysis, which allows for better interpretation of sophisticated genomic data. AI and ML are particularly good at recognizing genetic changes, comprehending the pathogenic mechanisms of diseases, and finding new therapeutic targets, which in turn fuels the need for targeting sequencing services.
In addition, the focus on multi omics approaches which integrate transcriptomics, proteomics, and metabolomics with genomics is increasing. As the research on the multi-omics approaches enables to provide deeper insight into the diseases and their molecular basis, it opens new possibilities for the development of advanced diagnostic and therapeutic tools. Moreover, dragging towards cheaper and more convenient representations of sequencing technologies are broadening their use in lower-grade clinics and research centers. In this new context of decentralized point of care testing, sequencing technologies are getting into the hands of healthcare professionals.
View Full Report with TOC & List of Figure: https://www.imarcgroup.com/targeted-dna-rna-sequencing-market
Targeted DNA/RNA Sequencing Market Dynamics:
Technology Insights:
- NGS
- Others
Workflow Insights:
- Presequencing
- Sequencing
- Data Analysis
Application Insights:
- Human Biomedical Research
- Plant and Animal Sciences
- Drug Discovery
- Others
Type Insights:
- DNA-based Targeted Sequencing
- RNA-based Targeted Sequencing
End User Insights:
- Hospitals & Clinics
- Academic & Research Institutes
- Pharma & Biotech Companies
Regional Insights:
- North America (USA, Canada)
- Europe (Germany, France, UK, Italy, Spain, Russia, others)
- Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, others)
- Middle East/Africa
- Latin America (Brazil, Mexico, others)
Targeted DNA/RNA Sequencing Market Leaders:
- Agilent Technologies Inc.,
- BGI Group,
- Dnastar Inc.,
- Eurofins Genomics LLC (Eurofins Scientific SE),
- Hoffmann-La Roche Ltd,
- Illumina Inc.,
- Integrated DNA Technologies,
- (Danaher Corporation),
- Macrogen Inc,
- Oxford Nanopore Technologies plc,
- PacBio,
- Pieriandx,
- QIAGEN N.V.,
- Thermo Fisher Scientific Inc.
About US:
IMARC Group is a global management consulting firm that helps the world’s most ambitious changemakers to create a lasting impact. The company provide a comprehensive suite of market entry and expansion services.
IMARC offerings include thorough market assessment, feasibility studies, company incorporation assistance, factory setup support, regulatory approvals and licensing navigation, branding, marketing and sales strategies, competitive landscape and benchmarking analyses, pricing and cost research, and procurement research.
Contact US:
IMARC Group
134 N 4th St. Brooklyn, NY 11249, USA
Email: sales@imarcgroup.com
Tel No:(D) +91 120 433 0800
United States: +1-631-791-1145
Comments
0 comment